23 active not recruiting. 23 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Active not recruiting 23 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Dermatitis, Atopic: new trials by email Literature Review of Dermatitis, Atopic trials Research Report on Dermatitis, Atopic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Topical Chinese Medicine and Exosome Mechanisms for Atopic Dermatitis menthol-based hand and foot gloves, Sham menthol-based hand and foot gloves - Atopic Dermatitis (AD) | Phase 2 | Active not recruiting | Taiwan Municipal An-Nan Hospital-China Medical University | 44 | 2026-04-29 | 2026-07-09 |
| A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis JNJ-95597528, Placebo - Dermatitis, Atopic | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 189 | 2026-01-20 | 2026-11-03 |
| A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis Afimkibart - Atopic Dermatitis | Phase 2 | Active not recruiting | Hoffmann-La Roche | 120 | 2026-01-08 | 2026-10-26 |
| A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis Galvokimig, Placebo - Atopic Dermatitis | Phase 2 | Active not recruiting | UCB Biopharma SRL | 165 | 2025-12-29 | 2026-09-25 |
| A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis KT-621, Placebo - Atopic Dermatitis | Phase 2 | Active not recruiting | Kymera Therapeutics, Inc. | 200 | 2025-11-24 | 2026-10-06 |
| Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis GIA632, Placebo - Atopic Dermatitis | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 34 | 2025-11-10 | 2026-05-14 |
| A Study Evaluating TRIV-509 in Atopic Dermatitis TRIV-509, Placebo - Atopic Dermatitis | Phase 2 | Active not recruiting | Triveni Bio | 95 | 2025-08-26 | 2026-04-27 |
| A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis BFB759, Placebo - Atopic Dermatitis (AD) | Phase 2 | Active not recruiting | Bluefin Biomedicine, Inc. | 225 | 2025-07-15 | 2026-07-30 |
| ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis ATI-045, Placebo - Atopic Dermatitis, Atopic | Phase 2 | Active not recruiting | Aclaris Therapeutics, Inc. | 110 | 2025-05-30 | 2026-09-29 |
| A Study for HSK44459 in Participants With Atopic Dermatitis HSK44459, Placebo - Atopic Dermatitis (AD) | Phase 2 | Active not recruiting | Xizang Haisco Pharmaceutical Co., Ltd | 150 | 2025-05-22 | 2026-01-02 |
| A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis Afimkibart, Placebo - Atopic Dermatitis | Phase 2 | Active not recruiting | Hoffmann-La Roche | 162 | 2025-04-01 | 2026-08-10 |
| A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis Lutikizumab, Placebo - Atopic Dermatitis | Phase 2 | Active not recruiting | AbbVie | 83 | 2024-12-19 | 2026-08-14 |
| A Study of Barzolvolimab in Patients With Atopic Dermatitis Barzolvolimab, Matching placebo - Atopic Dermatitis | Phase 2 | Active not recruiting | Celldex Therapeutics | 131 | 2024-12-18 | 2026-08-11 |
| A Study Evaluating APG777 in Atopic Dermatitis APG777, Placebo - Atopic Dermatitis | Phase 2 | Active not recruiting | Apogee Therapeutics, Inc. | 470 | 2024-04-29 | 2026-11-03 |
| A Study of TAVO101 in Atopic Dermatitis Patients TAVO101 - Atopic Dermatitis | Phase 2 | Active not recruiting | Tavotek Biotherapeutics | 20 | 2024-03-15 | 2024-11-18 |
| Evaluate the Safety, Tolerability of BAT6026 Monoclonal antibody BAT6026, sodium chloride injection - Dermatitis, Atopic | Phase 1 / Phase 2 | Active not recruiting | Bio-Thera Solutions | 33 | 2023-11-09 | 2026-10-02 |
| A Herbal Compound for Eczema ZAX.1400.EC.02, Placebo - Eczema, Atopic Dermatitis | Phase 2 | Active not recruiting | Fasa University of Medical Sciences | 110 | 2023-10-01 | 2025-01-06 |
| A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis PF-07275315, PF-07264660, Placebo - Atopic Dermatitis | Phase 2 | Active not recruiting | Pfizer | 507 | 2023-08-22 | 2026-10-23 |
| Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis Amlitelimab - Dermatitis Atopic | Phase 2 | Active not recruiting | Sanofi | 999 | 2023-04-03 | 2026-04-23 |
| Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) ADX-914, Placebo - Atopic Dermatitis | Phase 2 | Active not recruiting | Q32 Bio Inc. | 102 | 2022-09-30 | 2024-10-03 |
Showing 20 of 23. Sign in to see all of them.
Eczema (7) · Dermatitis (2) · Food Hypersensitivity (1) · Inflammation (1) · Pruritus (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (23) · Genetic Diseases, Inborn (23) · Hypersensitivity (23) · Hypersensitivity, Immediate (23) · Immune System Diseases (23) · Skin Diseases (23) · Skin Diseases, Eczematous (23) · Skin Diseases, Genetic (23) · Skin and Connective Tissue Diseases (23) · Dermatitis (21) · Pathological Conditions, Signs and Symptoms (2) · Pathologic Processes (1) · Signs and Symptoms (1) · Skin Manifestations (1)
Adrenal Cortex Hormones (1) · Calcineurin Inhibitors (1) · EpiCeram (1) · Sodium Chloride (1) · Standard of Care (1) · lutikizumab (1)
Hoffmann-La Roche (2) · Sanofi (2) · AbbVie (1) · Aclaris Therapeutics, Inc. (1) · Apogee Therapeutics, Inc. (1) · Bio-Thera Solutions (1) · Bluefin Biomedicine, Inc. (1) · Celldex Therapeutics (1) · EHL Bio Co., Ltd. (1) · Fasa University of Medical Sciences (1) · Janssen Research & Development, LLC (1) · Kari Nadeau, MD, PhD (1) · Kymera Therapeutics, Inc. (1) · Novartis Pharmaceuticals (1) · Pfizer (1)
United States (17) · Canada (13) · Poland (12) · Germany (11) · Czechia (8) · Japan (7) · China (6) · Spain (6) · United Kingdom (6) · Australia (5) · Brazil (5) · Bulgaria (5) · France (5) · South Korea (5) · Hungary (4)
Donghun Lee, M.D, Ph.D (1) · Kari Nadeau, MD, PhD (1) · Mingyeong Shin, M.D, Ph.D (1) · Penelope Montgomery, MD (1) · Sanguk Son, M.D, Ph.D (1) · Seongjun Seo, M.D, Ph.D (1) · Soyeon Jo, M.D, Ph.D (1) · Young-joon Seo, M.D, Ph.D (1)
PMID 40739793, PMID 41331725, PMID 41422501
2025 (5), 2023 (2), U01AI147462 (1)